Abraham Park, MD
Ophthalmology · Kansas City, MONPI 1346530441
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,946 of the $5,678 with a category attached, or 69.5%. 21 manufacturers reported payments, led by Alcon at 40.9% of the total.
Across 142 payments — averaging $39.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$2K
- AbbVie$1K
- Glaukos Corporation$566
- Alcon Research LLC$328
- Sight Sciences, Inc.$228
- Rayner Intraocular Lenses Limited$177
- plus $639 from 15 others
Across 102 payments — averaging $2135.49 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$119K
- Glaukos Corporation$69K
- Alcon Research LLC$30K
What the payments were for
- Consulting fees$1062%
- Travel & lodging$1,47926%
- Food & beverage$3,94669%
- Education$1473%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 29 | $2,323 |
| AbbVie(2 entities) | 70 | $1,418 |
| Glaukos Corporation | 11 | $566 |
| Alcon Research LLC | 1 | $328 |
| Sight Sciences, Inc. | 6 | $228 |
| Rayner Intraocular Lenses Limited | 1 | $177 |
| Ivantis, Inc | 1 | $121 |
| Aerie Pharmaceuticals, Inc. | 5 | $102 |
| NEW World Medical,inc. | 2 | $63 |
| Bausch & Lomb Americas Inc. | 3 | $62 |
| Novartis | 1 | $59 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $45 |
| Harrow Eye, LLC | 2 | $35 |
| Mallinckrodt Hospital Products Inc. | 1 | $25 |
| Amgen | 1 | $22 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $20 |
| Ocular Therapeutix, Inc. | 1 | $19 |
| Sun Pharmaceutical Industries Inc. | 1 | $18 |
| Eyevance Pharmaceuticals LLC | 1 | $17 |
| Omeros Corporation | 1 | $17 |
| Kala Pharmaceuticals, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Clareon$836
- LenSx$836
- Unity$836
- Wavelight Refractive Suite$836
- Voyager DSLT$836
- RAYNER CATARACT SET 1$177
- RayOne EMV$177
- RayOne Spheric$177
- RayOne Aspheric$177
- Hydrus Microstent$153
- iStent Trabecular Micro-Bypass Stent System$142
- iStent inject Trabecular Micro-Bypass Stent System$142
- iDose$137
- OMNI(R) SURGICAL SYSTEM (US)$135
- AcrySof$132
- Centurion$125
- Hydrus$121
- XEN GLAUCOMA TREATMENT SYSTEM$115
- DURYSTA$110
- XEN$106
How this compares
$5,678 in reported general payments places this provider in the 80th percentile of 286 ophthalmology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 138 | $54,123 |
| Prednisolone Acetate | 690 | $30,230 |
| RestasisCyclosporine | 31 | $21,428 |
| CombiganBrimonidine Tartrate/Timolol | 49 | $18,745 |
| RhopressaNetarsudil Mesylate | 29 | $9,721 |
| VyzultaLatanoprostene Bunod | 26 | $8,919 |
| Latanoprost | 828 | $7,828 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 349 | $6,488 |
| Brimonidine Tartrate | 144 | $5,749 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 26 | $5,560 |
| Travoprost | 33 | $5,453 |
| TafluprostTafluprost/Pf | 17 | $3,706 |
| Dorzolamide-TimololDorzolamide/Timolol/Pf | 11 | $3,643 |
| Tobramycin | 511 | $2,826 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 17 | $2,764 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Combigan | $1,418 | $94,297218 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa | $102 | $9,72129 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $62 | $8,91926 claims |
| AlconSimbrinza | $2,323 | $5,56026 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 286 ophthalmology providers in Missouri.
Other ophthalmology in Kansas City
- Steven SilversteinKansas City$872K
- Joseph TauberKansas City$174K
- Stephen WilesKansas City$13K
- Michelle BoyceKansas City$10K
- Lindsey McDanielKansas City$5K
- Ranjan MalhotraSaint Louis$809K
- Nancy HolekampChesterfield$768K
- Jay PeposeChesterfield$516K
- Gregg BerdySaint Louis$360K
- Joseph GiraDes Peres$174K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.